These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 23609047)

  • 1. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay.
    Baccelli I; Schneeweiss A; Riethdorf S; Stenzinger A; Schillert A; Vogel V; Klein C; Saini M; Bäuerle T; Wallwiener M; Holland-Letz T; Höfner T; Sprick M; Scharpff M; Marmé F; Sinn HP; Pantel K; Weichert W; Trumpp A
    Nat Biotechnol; 2013 Jun; 31(6):539-44. PubMed ID: 23609047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression.
    Szostakowska-Rodzos M; Fabisiewicz A; Wakula M; Tabor S; Szafron L; Jagiello-Gruszfeld A; Grzybowska EA
    Sci Rep; 2024 Jun; 14(1):12924. PubMed ID: 38839863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonality of circulating tumor cells in breast cancer brain metastasis patients.
    Riebensahm C; Joosse SA; Mohme M; Hanssen A; Matschke J; Goy Y; Witzel I; Lamszus K; Kropidlowski J; Petersen C; Kolb-Kokocinski A; Sauer S; Borgmann K; Glatzel M; Müller V; Westphal M; Riethdorf S; Pantel K; Wikman H
    Breast Cancer Res; 2019 Sep; 21(1):101. PubMed ID: 31481116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients.
    Perelmuter VM; Grigoryeva ES; Savelieva OE; Alifanov VV; Andruhova ES; Zavyalova MV; Bragina OD; Garbukov EY; Menyailo ME; Khozyainova AA; Denisov EV; Cherdyntseva NV; Tashireva LA
    Sci Rep; 2024 May; 14(1):12245. PubMed ID: 38806508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and quantitative method to detect human circulating tumor cells in a preclinical animal model.
    Tu SH; Hsieh YC; Huang LC; Lin CY; Hsu KW; Hsieh WS; Chi WM; Lee CH
    BMC Cancer; 2017 Jun; 17(1):440. PubMed ID: 28645267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome‑wide copy number analysis of circulating tumor cells in breast cancer patients with liver metastasis.
    Zou L; Imani S; Maghsoudloo M; Shasaltaneh MD; Gao L; Zhou J; Wen Q; Liu S; Zhang L; Chen G
    Oncol Rep; 2020 Sep; 44(3):1075-1093. PubMed ID: 32705227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients.
    Baccelli I; Stenzinger A; Vogel V; Pfitzner BM; Klein C; Wallwiener M; Scharpff M; Saini M; Holland-Letz T; Sinn HP; Schneeweiss A; Denkert C; Weichert W; Trumpp A
    Oncotarget; 2014 Sep; 5(18):8147-60. PubMed ID: 25230070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
    Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
    Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.
    Vishnoi M; Liu NH; Yin W; Boral D; Scamardo A; Hong D; Marchetti D
    Mol Oncol; 2019 Sep; 13(9):1913-1926. PubMed ID: 31216110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
    Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
    Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells.
    Nini A; Hoffmann MJ; Lampignano R; Große Siemer R; van Dalum G; Szarvas T; Cotarelo CL; Schulz WA; Niederacher D; Neubauer H; Stoecklein NH; Niegisch G
    Cytometry B Clin Cytom; 2020 Jul; 98(4):355-367. PubMed ID: 32212383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
    Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis.
    Sharma U; Medina-Saenz K; Miller PC; Troness B; Spartz A; Sandoval-Leon A; Parke DN; Seagroves TN; Lippman ME; El-Ashry D
    Breast Cancer Res Treat; 2021 Aug; 189(1):63-80. PubMed ID: 34216317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.